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PolyspeciﬁcityP-glycoprotein (Pgp) is an important contributor to multidrug resistance of cancer. Pgp contains eleven native
tryptophans (Trps) that are highly conserved amongorthologs.We replaced each Trpby a conservative substitution
to determine which Trps are important for function. Individual Trp mutants W44R, W208Y, W132Y, W704Y and
W851Y, situated at the membrane surface, revealed signiﬁcantly reduced Pgp induced drug resistance against
one ormore fungicides and/or reducedmating efﬁciencies in Saccharomyces cerevisiae. W158F andW799F, located
in the intracellular coupling helices, abolished mating but retained resistance against most drugs. In contrast,
W228F and W311Y, located within the membrane, W694L, at the cytoplasmic membrane interface, and W1104Y
in NBD2 retained high levels of drug resistance and mating efﬁciencies similar to wild-type Pgp. Those were com-
bined into pair (W228F/W311Y andW694L/W1104Y) and quadruple (W228F/W311Y/W694L/W1104Y) mutants
that were fully active in yeast, and could be puriﬁed to homogeneity. Puriﬁed pair and quad mutants exhibited
drug-stimulated ATPase activity with binding afﬁnities very similar to wild-type Pgp. The combined mutations
reduced Trp ﬂuorescence by 35%, but drug induced ﬂuorescence quenching was unchanged from wild-type Pgp
suggesting that several membrane-bound Trps are sensitive to drug binding. Overall, we conclude that Trps at
the membrane surface are critical for maintaining the integrity of the drug binding sites, while Trps in the coupling
helices are important for proper interdomain communication. We also demonstrate that functional single Trp
mutants can be combined to form a fully active Pgp thatmaintains drug polyspeciﬁcity, while signiﬁcantly reducing
intrinsic ﬂuorescence.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
P-glycoprotein (Pgp, also known as ABCB1) is an integralmembrane
protein that functions as a multidrug exporter [1]. Pgp binds a wide
array of structurally unrelated compounds, including many commonly
used drugs, and transports them to the extracellular matrix, preventing
intracellular drug accumulation [2,3]. Pgp mediated drug transport is a
well-known contributor to multidrug resistance of cancer cells, and
Pgp expression in tumors is associated with poor treatment outcome
and patient relapse [4–6]. Pgp is also expressed at the blood brain
barrier, intestinal epithelium and other sites where it can cause
resistance to chemotherapeutic treatment for a variety of diseases
including HIV infection and epilepsy [7–10]. Despite nearly four
decades of work and multiple generations of clinical trials, a clinicallycassette; TMD, Transmembrane
ophan; DDM, n-Dodecyl-β-D-
MPC, 1-palmitoyl-2-myristoyl-
logy and Biochemistry, Texas
79430, USA. Tel.: +1 806 743
ch).
rights reserved.viable Pgp inhibitor has remained elusive, substantiating the need for
more in depth studies of the Pgp drug transport mechanism [11,12].
Pgp is a member of the ATP binding cassette (ABC) transporter
superfamily [13]. It consists of two transmembrane domains (TMDs)
with six α-helices and two nucleotide binding domains (NBDs) that
bind and hydrolyze ATP [14]. The Pgp crystal structure (PDB: 3G5U,
Fig. 1) reveals that the two TMDs combine to form a voluminous
central cavity with multiple sites for polyspeciﬁc substrate binding,
which is likely mediated through varying interactions with amino
acid side chains lining the central cavity [15–18]. The NBDs can
dimerize to form two nucleotide binding sites that are catalytically
active [19,20]. Nucleotide binding induced NBD dimerization likely
provides the power to rearrange the TMDs from an inward-facing
conformation, where transport substrates are able to enter the central
cavity from the lipid bilayer or cytoplasm, to an outward-facing
conformation that exposes the central cavity and bound substrates
to the extracellular environment [21]. However, details of how sub-
strate binding and transport are achieved through coordinated move-
ments of the NBDs and TMDs remain poorly understood for Pgp and
ABC transporters in general [22,23]. Site-speciﬁc tryptophan ﬂuores-
cence spectroscopy, with probes placed at strategic sites, has been
previously used with a variety of membrane proteins to monitor
substrate binding and conformational changes that occur during the
Fig. 1. Location of the eleven endogenous Trps in Pgp. Pgp crystal structure with the
N-terminal and C-terminal homologous protein halves shaded in blue and green, respective-
ly, and theTrpshighlighted in red spheres. Dashed lines indicate the approximateboundaries
of the lipid bilayer; ICL, intracellular loops; TMD, transmembrane domain; NBD1 and NBD1,
N-terminal and C-terminal nucleotide binding domains, respectively.W44 andW694/W704
are located in the elbow helices that precede the N- and C-terminal TMDs, respectively.
W158 andW799 are located in the ICL 2 and ICL4 couplinghelices, respectively, that connect
the TMDs to the NBDs. Images were rendered in PyMol (www.pymol.org) using PDB: 3G5U.
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invasive when compared to extrinsic ﬂuorophores that must be cova-
lently attached to the protein. Trp, as a ﬂuorophore, eliminates label-
ing stoichiometry uncertainty (as it can be inserted genetically), and
minimizes the risk of affecting protein structure and/or function,
due to its relatively small size. However, site-speciﬁc Trp ﬂuorescence
has been precluded from use with Pgp due to the presence of eleven
endogenous Trps that contribute to a high intrinsic ﬂuorescence
emission (Fig. 1). Two Trps (W208 and W851) are located in extra-
cellular loops close to the membrane bilayer interface, two (W311
and W228) are within the hydrophobic core of the membrane,
W132 and three Trps in the elbow helices (W44, W694 and W704)
are located at the cytoplasmic membrane interface, two (W158 and
W799) are in the coupling helices that connect the TMDs to the
NBDs, and W1104 is in NBD2. Sharom and colleagues have previously
reported that intrinsic Pgp ﬂuorescence is quenched by 20 to 50%
upon binding of various cancer drugs [27]. However, eight Pgp Trps
are located in the membrane domains (Fig. 1), close enough to
respond to drug binding via FRET, making it difﬁcult to dissect which
and how many Trps were responsible for the observed quenching.
Intrinsic Pgp ﬂuorescence must be reduced or eliminated to allow the
use of newly-inserted Trps to localize the discrete drug binding sites
within the drug binding cavity and gain insights into how the NBDs
and TMDs communicate with one another to transport so many differ-
ent compounds.
Trp is generally the least abundant, but most conserved amino
acid in a protein [28]. The aromatic amino acids, tyrosine and phenyl-
alanine, have often been used to replace Trps while maintaining
interactions that may be necessary for function, but in some situa-
tions another amino acid may be a better replacement depending
on the local environment of the Trp residue [29,30]. A Trp-less Pgp
was previously constructed by replacing all eleven Trps with phenyl-
alanine. However, this protein exhibited low expression and minimal
activity rendering it unsuitable for biochemical and biophysical studies
[31]. In this study, we systematically analyzed the eleven endogenous
Pgp Trps to identify which Trps could be replaced while maintaining
protein expression and function. At each Trp position, we tested
aromatic substitutions except where alignment with orthologous
sequences suggested another amino acid substitution. The mutants
with a single Trp removed were expressed in Saccharomyces cerevisiae
to determine which mutants maintained Pgp function based on theirability to convey resistance against multiple fungicidal compounds,
and complement for Ste6, a Pgp homolog required for yeast mating.
Mutants that were fully active in these assays were then combined
into multi-Trp mutant proteins, puriﬁed, and catalytic ability of these
proteins was measured through drug-stimulated ATPase activities.
Overall, we found that multiple Trps could be removed from Pgp while
maintaining protein function and drug polyspeciﬁcity, but signiﬁcantly
reducing intrinsic ﬂuorescence.
2. Materials and methods
2.1. Materials
FK506 and valinomycin were purchased from A.G. Scientiﬁc
(San Diego, CA). Fluconazole was from LKT Laboratories (Saint Paul,
MN). Doxorubicin, verapamil, cyclosporin A, and ATP were from Sigma
Aldrich (Saint Louis, MO). E. coli lipids (Polar Extract) and PMPC were
purchased from Avanti (Alabaster, AL), n-Dodecyl-β-D-maltopyranoside
(DDM) was from Inalco (Italy).
2.2. Mutant construction and analysis in S. cerevisiae
Wt mouse Pgp (mdr3, abcb1a) in the pVT expression vector
(pVT-mdr3.5) [32,33] served as a template throughout this study.
Individual Trp mutations were introduced by QuickChange (Stratagene)
site-directed mutagenesis using oligonucleotides containing the Trp mu-
tation and silent mutations to identify themutants by restriction enzyme
digestion (all mutagenic oligonucleotides are listed in Supplementary
Table 1). To generate the two Trp pair mutants, W311Y was introduced
into the W228F ORF and W694L was introduced into the W1104Y ORF
by site-directed mutagenesis. Then W228F/W311Y were combined
with W694L/W1104Y by subcloning with SacI sites that ﬂank W228F
and W311Y to form the quadruple mutant W228F/W311Y/W694L/
W1104Y (Quad). Mutant constructs were conﬁrmed by DNA sequencing
of the entire Pgp open reading frame.Wild-type abcb1 (Wt) and Trpmu-
tantswere then transformed into S. cerevisiae, JPY201(MATa ura3Δste6::
HIS3), cells for expression and functional assays that were performed
essentially as previously described [33–36]. Brieﬂy, 10 ml yeast cultures
were grown overnight in uracil deﬁcientmedium containing 7.5% glycer-
ol, diluted toOD600=0.05 in YPDmedium, and seeded into 96well plates
containing YPD alone or YPD plus 50 μM FK506, 100 μM valinomycin or
40 μM doxorubicin. Samples were grown in triplicate at 30 °C for up to
30 hours, and yeast cell growth was monitored by measuring the OD600
at two hour increments in amicroplate reader (Benchmark Plus, BioRad).
The concentrations of drugs were ﬁne-tuned to give maximum growth
differences between Wt and pVT vector controls [35]. The remainder of
the 10 ml cultures were used for microsomal membrane preparations
to assess Pgp expression by Western blot analysis as described [35].
Statistical analyses of the functional assayswere donewith the SigmaPlot
11 software using a two-tail t-test.
2.3. Large scale Trp mutant expression and puriﬁcation
For protein puriﬁcation,Wt and mutant plasmids were transformed
into strain BY4743 (relevant phenotype: MAT a/α ura3Δ0) [37],
for increased biomass production versus JPY201 cells (provided by
Dr. Brandt L. Schneider), and grown in 15 L fermentor cultures (BioFlow
IV, New Brunswick) containing uracil deﬁcient medium supplemented
with 7.5% glycerol, as a chemical chaperone, to enhance Pgp expres-
sion [38]. Cells were harvested during log-phase growth (A280=6–7)
yielding 60–90 g cells per fermentor culture. Microsomal membranes
were prepared as described for Pichia pastoris cells [36]. Wt andmutant
Pgp proteins were extracted in 0.6% DDM and puriﬁed with successive
nickel afﬁnity, DE-52 anion exchange, and size exclusion chromatogra-
phy steps, as previously described for P. pastoris expressed Pgp [35,36].
Protein concentration of Pgp containing fractions was determined by
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coefﬁcient of 109,750 M−1 cm−1 (1 A280 unit=1.29 mg/ml). Wt and
mutant proteins were further quantitated by resolving increasing
protein amounts on Coomassie stained SDS-PAGE gels and compared
to a BSA standard using ImageJ (http://rsbweb.nih.gov/).
2.4. ATPase assays
For ATPase activity measurements, we modiﬁed the malachite
green assay for detection of inorganic phosphate (Pi) release [39,40]
for use with small volumes in a 96 well plate format as follows: Wt
and mutant proteins in 0.1% DDM were activated with 10 mM DTT
for 10 min on ice, and then mixed with an equal volume of 2%
E. coli lipids and incubated at RT for 15 minutes [36]. Then, 0.1 μg
activated protein was added to wells of a 96 well plate containing
10 μl of 10 mM ATP cocktail (10 mM ATP, 10 mM MgSO4 in 50 mM
Tris-Cl buffer pH 7.5) with a 2-fold serial dilution of verapamil, FK506,
valinomycin, or cyclosporin A with 150 μM verapamil, pre-warmed to
37 °C. ATPase reactionswere stopped at times ranging from 0 to 30 mi-
nutes by the addition of 100 μl cold 0.4 NH2SO4 containing 0.05 %DDM,
and the 96 well plates were transferred to ice. Pi was measured by
adding 100 μl of a stock color development solution to give a ﬁnal
concentration of 0.73% ammonium molybdate, 0.9 N H2SO4, 0.056%
polyvinyl alcohol, and 0.011% malachite green in each sample well.
Samples were then incubated at RT for 20 min and the absorbance of
each sample was measure at 610 nm in a microplate reader (Bench-
mark Plus, BioRad). Mock samples containing buffer and lipids without
any added Pgp were subtracted as background values, and inorganic
phosphate standards (from 0.5 to 10 nmol) served as internal controls.
2.5. Statistical analysis
Signiﬁcant differences in the yeast functional assayswere determined
using Student's t-test with p=0.05 as the rejection limit. The ATPase
activities for stimulatory compounds were analyzed by nonlinear re-
gression analysis using the equation V=Vbas+(Vmax×Sb)/(Sb+Ksb),
where S is the concentration of stimulatory drug, V is the rate of ATP hy-
drolysis, Vbas is the ATPase activity in the absence of drug, Vmax is the
maximum drug stimulated ATPase activity, Ks is the concentration of
drug required for half-maximal stimulation, and b is the Hill coefﬁcient.
Cyclosporin A inhibition was analyzed using the equation V=
Vbas−((Vbas− Imax)× Ib) /(Kib+ Ib) where I is the inhibitor concen-
tration, Imax is the maximal inhibited ATPase activity, and Ki is
the inhibitor concentration required for half-maximal inhibition.
The Hill coefﬁcient for a given drug was similar between Wt
and mutant proteins and was between ~1 for verapamil, FK506,
and cyclosporin A, and ~2 for valinomycin. For each data ﬁt, R2
was greater than 0.97 and each of the parameters was statistically
signiﬁcant (pb0.05). Wt and mutant Ks values were compared by
Student's t-test. All statistical analyses were performed with Sigmaplot
11.
2.6. Tryptophan ﬂuorescence
Pgp intrinsic Trp ﬂuorescence was measured by diluting puriﬁed
proteins to 100 nM with puriﬁcation buffer (20 mM HEPES, 50 mM
NaCl, 10% glycerol, 0.1% DDM, pH 7.4) and measuring the steady
state ﬂuorescence emission from 310 to 410 nm with an excitation
wavelength of 295 nm in a Fluorolog-3 spectroﬂuorometer (Horiba)
at room temperature. Emission spectra were corrected by comparing
the technical spectra of tyrosine and tryptophan with the corrected
spectra as given by Eftink [41]. Rhodamine binding studies were
performed in 20 mM HEPES, pH 7.4, 150 mM NaCl, 0.125% CHAPS,
0.5 mg/ml PMPC. Drug was added from concentrated stock in DMSO
such that the ﬁnal DMSO concentration was b1%, buffer controls
containing the same amount of rhodamine/DMSO were subtractedfrom each sample. Inner ﬁlter corrections were carried out using
NATA. Data were analyzed by nonlinear regression analysis using
the equation f=d−(a×Sb)/(Sb+Kqb), where S is the concentration
of drug (rhodamine 123), a is the maximum quench, d is the Trp
ﬂuorescence in the absence of drug, Kq is the concentration of drug
required for half-maximal quenching, and b is the Hill coefﬁcient.
3. Results
3.1. Single Trp mutant expression
Our ﬁrst objective was to mutate each of the eleven Pgp Trps, and
determine how removing individual Trps affects protein expression
and function. First, we compared Pgp amino acid sequences from
different species to identify Trp substitutions that may preserve
function. Human and mouse Pgp were aligned with orthologous Pgp
sequences, having greater than 70% sequence identity, from the
Ensembl database (http://ensembl.org) [42]. Nine of the eleven
Trps were completely conserved across the 45 aligned orthologs.
At W44, we found that Trp was replaced by arginine in guinea pig
(Cavia porcellus), cysteine in chicken (Gallus gallus), and threonine
in frog (Xenopus laevis) Pgp (Supplementary Fig. 1A). We chose
arginine to replace W44 since guinea pig is the closest relative to
mouse and human. At W694, phenylalanine occurs in opossum
(Monodelphis domestica) and frog, and leucine is present in chicken
and turkey (Meleagris gallopavo) (Supplementary Fig. 1B). We chose
leucine to replace this Trp because ABCB4, a Pgp paralog, in mouse
and several of its orthologous sequences also have leucine instead of
Trp at W694. For the remaining six Trps located in the lipid bilayer or
at the membrane interface (Fig. 1), we chose tyrosine to replace Trp
because membrane snorkeling preferences predict that it interacts
more favorably with the lipid bilayer than phenylalanine [43–45]. The
two Trps in the coupling helices (W158 and W799) were replaced by
phenylalanine, found in the related bacterial ABC transporters MsbA
and Sav1866 [46,47], and W1104 in NBD2 was replaced by a tyrosine.
Each of these single mutants was transformed into S. cerevisiae for
analysis of protein expression and function. Western blots revealed
that the mutants were abundantly expressed as a full-length protein,
at levels similar to or greater than Wt Pgp, except W228Y (Fig. 2A).
W228Y exhibited severely diminished levels of full-length protein and
accumulation of a truncated mutant with an approximate molecular
weight of 50 kDa. This result was reproducible with multiple clones of
the mutant suggesting that tyrosine at this position adversely affects
protein synthesis, folding, or trafﬁcking. Subsequently, we replaced
this membrane bound Trp (Fig. 1) with phenylalanine, and found that
the more hydrophobic W228F mutation is well expressed when
compared to Wt Pgp (Supplemental Fig. 2). Together, these data
suggests that no single endogenous Trp was critical for Pgp expression.
3.2. Single Trp mutant function
Previous work has demonstrated that when Pgp is expressed in
S. cerevisiae, it can convey fungicidal resistance to the yeast cells [34].
Furthermore, Pgp can complement for Ste6, the a-factor pheromone
transporter required formating, and restoremating in otherwise sterile
Ste6 null yeast [33]. When the yeast strains expressing mutant Pgp
were exposed to FK506, only three mutants (W44R, W208Y, and
W851Y) had relative growths rates that were signiﬁcantly less than
strains expressingWt (* in Fig. 2B, p=0.0004, 0.001, 0.05, respectively).
However, the mating efﬁciencies were severely impaired (b40% of Wt)
in ﬁve of the mutants (Fig. 2C) with W208Y showing low functionality
in both assays. W311Y andW1104Y performed well at levels similar to
Wt in both the mating and FK506 resistance assays while W228F and
W694L outperformed Wt in mating efﬁciency by approximately 2 fold
and maintained high levels of FK506 resistance. Interestingly, W44R
had opposing effects in the two assays. This mutant signiﬁcantly
Fig. 2. Expression and function of single Trp mutants in yeast. A, 15 μg of crude microsomal
membrane protein fromyeast expressingWt Pgp, empty vector (negative control), and each
Trp mutant was analyzed by Western blot using the C219 anti-Pgp antibody. A representa-
tive of at least three experiments is shown; protein MW marker positions are indicated in
kDa. B, Fungicidal resistancewasmeasured by growingmutant expressing yeast and control
strains in the absence or presence of 50 μM FK506 and measuring the OD600 at 24 to
25 hours. Relative growth is the OD600 of cells grown in drug/the OD600 of cells grown in
drug-free medium. Bars represent the mean relative growth±SEM of triplicate samples
from three or more independent experiments normalized to the relative growth of yeast
expressing Wt Pgp. C, Mating efﬁciency of Trp mutants was determined by mating the
a-type Trp mutant expressing cells with an α-type tester strain and plating on minimal
media selective for diploids. Relativemating efﬁciency is the number of diploid cells divided
by the total number of cells, then divided by the mating efﬁciency of Wt expressing yeast.
Bars indicate the mean relative drug resistance±SEM from four independent experiments.
(*) indicate samples that were signiﬁcantly different than Wt using a two tail t-test with
p≤0.02.
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FK506 resistance. Overall, the combined results of these two functional
assays identiﬁed a set of single Trp mutants (W228F, W311Y, W694L,
and W1104Y) that likely preserve Pgp function at the plasma
membrane based on FK506 transport (a macrocyclic lactone, MW of
804 g/mol) and export of yeast a-factor (a farnesylated dodecapeptide),
compounds with vastly different sizes and structures [48].
The differing performance of mutants with the two transport
substrates suggested that some Trp mutations may not simply impair
the protein, but may alter its speciﬁcity for some substrates. We further
explored this possibility by subjecting the yeast strains to growth in
three additional fungicidal drugs, valinomycin (1111 g/mol), ﬂucona-
zole (306 g/mol), and doxorubicin (544 g/mol), that represent a
structurally diverse set of compounds. Most mutants retained some
level of resistance (>50%) against these drugs except for W158F,
which behaved similar to the vector control in ﬂuconazole (b20%
growth, Fig. 3). Again, W694L and W1104Y, maintained a high level of
activity (>70%) across all transport substrates assayed (Fig. 3, see also
Fig. 2B, C). W228F and W311Y retained signiﬁcant levels of drug resis-
tance in all but one of the drugs (doxorubicin orﬂuconazole, respective-
ly). Interestingly,W44R andW851Y, whichwere signiﬁcantly impaired
in FK506 (Fig. 2B) but mated efﬁciently (Fig. 2C), also maintained high
levels of resistance against all three additional drugs. Together, these
data indicate that the ability to mate (Fig. 2C) is a stringent ﬁrst test
for function. However, drug resistance proﬁles may be altered in
individual mutants and should be tested to conﬁrm that polyspeciﬁcity,
a hallmark of Pgp function, is maintained.
3.3. Functionality of combined Trp mutations
Our second objective was to determine how Pgp would be affected
when multiple single Trp substitutions were combined into the same
protein. Based on the functional data we ﬁrst paired W228F/W311Y as
well as W694L/W1104, because each of these single mutants were
statistically equivalent to Wt in both the FK506 assay and the mating
assay (Fig. 2B and C). Coincidentally, these four Trps have previously
been predicted to be major contributors to the Trp ﬂuorescence
lifetimes of Pgp [49]. Then W228F/W311Y was added to W694L/
W1104Y to form the quadruple mutant W228F/W311Y/W694L/
W1104Y (Quad). The pair and quadmutants exhibited expression levels
similar to Wt (data not shown), maintained high levels of FK506 resis-
tance (Fig. 4A), and outperformed Wt in mating efﬁciency, similar to
the respective single mutants (Fig. 4B).These data suggest that the
double and quadmutants combine the properties of the single mutants,
or in other words the combinations were successful because we started
with fully active single mutants.
As proof of principle, we also combinedW132Y,W158F, andW311Y
(N-triple mutant). All three individual mutants were highly resistant to
FK506 (Fig. 2B), but W132Y andW158F had signiﬁcantly lower mating
efﬁciencies than Wt. Additionally, each mutant showed signiﬁcantly
reduced resistance to one of the other drugs (W132Y to valinomycin,
W158F to ﬂuconazole, and W311Y to doxorubicin, see Fig. 3). Com-
bining these mutations completely ablated FK506 resistance (Fig. 4A),
even though protein expression was not impaired (data not shown).
The N-triple mutant strain was also sterile in the yeast mating assay
(Fig. 4B) as expected from the low mating efﬁciencies of the respective
W132Y andW158Fmutants. The stark functional contrast between the
N-triple mutant and Quad mutant demonstrates the importance of
thoroughly testing individual Trp mutations before attempting to use
them to construct a low-tryptophan Pgp protein that is functional.
3.4. Functionality of puriﬁed double and quad Trp mutations
Our third objective was to examine the function of the combined
pair and Quad mutants and their interaction with drug substrates at
the puriﬁed protein level. Wt and the combination mutants were
Fig. 3. Fungicidal resistance proﬁles of single Trp mutant expressing yeast strains.
Mutant and control strains were analyzed for resistance to 75 μM (A) valinomycin,
65 μM ﬂuconazole (B), and 25 μM doxorubicin (C) as in Fig. 2B. Bars indicate the
mean relative growth±SEM of duplicate samples from four independent experiments,
normalized toWt relative growth. (*) indicate mutants that were signiﬁcantly different
than Wt (pb0.05).
Fig. 4. Functionality of combined Trp mutations. A, Relative resistance of mutant and
control strains to 60 μMFK506. Bars indicate themean relative growth±SEM of triplicate
samples, normalized to Wt, from ﬁve independent experiments. B, Relative mating efﬁ-
ciency±SEM of ﬁve independent experiments. (*) indicate samples that are signiﬁcantly
different than Wt (pb0.01). N-triple mutant: W132Y/W158Y/W311Y; Quad mutant:
W228F/W311Y/W694L/W1104Y.
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same procedures we previously described for puriﬁcation of Pgp
from Pichia pastoris yeast (see Experimental Procedures). The last
step involved size exclusion chromatography to remove residualcontaminants, and exchange the proteins into a deﬁned buffer for fur-
ther biochemical and biophysical studies. Wt and mutant proteins all
eluted as a sharp peak consistent with monomeric protein [35], well
separated from smallermolecularweight proteins (labeled “impurities”
in Fig. 5A). Coomassie-stained SDS-gels revealed that Wt and each
mutant protein were puriﬁed to near homogeneity (Fig. 5B). Mutant
protein yields were consistent with the Wt Pgp yield of 1.3 mg Pgp/
fermentor culture (Table 1), which is somewhat lower than from Pichia
pastoris [35]. However, the protein purity was excellent and the protein
quantity is sufﬁcient for biochemical and biophysical studies.
The drug stimulated ATPase activity of the puriﬁed proteins was
evaluated, as this has long been a standard measure of in vitro Pgp
function [36,50]. The maximum verapamil-stimulated ATPase activity
of the puriﬁed pair and quad mutants was very similar to Wt Pgp, with
verapamil providing a 5-fold stimulation in ATPase activity (Table 1).
Half-maximal stimulatory concentration for verapamil ranged from 9 to
16 μM for Wt and the mutants (Fig. 6A, Table 2), not signiﬁcantly differ-
ent in a two tail t-test (p=0.05), andwas in the same range as previously
published [35]. Maximum stimulation of ATPase activity by valinomycin
and FK506 was lower than with verapamil, about 4-fold and 3-fold over
Fig. 5. Puriﬁcation of Wt and Trp mutant Pgp from S. cerevisiae. A, Two milligrams
(500 μl) of puriﬁed, detergent soluble proteins were loaded on a Superose 6B column
(10×300 mm, GE Healthcare) and resolved in buffers containing 20 mM Hepes-NaOH
pH7.4, 10% glycerol, 50 mMNaCl, 1 mMDTT and 0.1%DDMas described [35]. A represen-
tative of four independent runs is shown for WT-Pgp and the mutant proteins. The Pgp
peak at ~15.3 ml indicates an apparent size of ~200 kDa when compared to molecular
mass markers resolved under identical buffer conditions [35]. The calculated molecular
mass of monomeric Pgp (including the His6-tag) is 142 kDa, the predicted detergent
micelle size for DDM is about 70 kDa. B) 1, 2, and 3 μg of Wt and mutant proteins were
resolved on a 10% SDS-PAGE and stained with Coomassie blue. Protein MW marker
positions are shown in kDa.
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70 μM and 20 μM, respectively (Fig. 6B and C). Again, the half-maximal
stimulatory concentrations for valinomycin and FK506 of Wt and the
mutants proteins were not signiﬁcantly different in the two tail test
(p=0.05, Table 2). Inhibition of verapamil-stimulated ATPase activity
by the immunosuppressant cyclosporin A was also comparable for the
Wt and mutant proteins, with half-maximal inhibition seen at 10–
15 μM (p=0.05 Fig. 6D). Together these data indicate that the mutants
were very similar to Wt Pgp in terms of yield, purity and their afﬁnities
for substrates and inhibitors in the puriﬁed proteins.Table 1
Yield and ATPase activity of Wt and Trp mutant proteins.
Yield
(mg/fermentor culture)a
ATPase activityb
(μmole Pi mg−1 min−1)
Wt 1.3 0.49±0.02
W228F/W311Y 1.5 0.54±0.03
W694L/W1104Y 1.4 0.30±0.01
Quad 1.1 0.63±0.08
a A 15 l fermentor culture routinely gives between 80 and 90 g of wet cells.
b Maximum drug-stimulated ATPase activity in the presence of 125 μM verapamil
(mean±SEM).3.5. Intrinsic tryptophan ﬂuorescence of Wt and mutant proteins
The goal of removing Pgp Trps was to minimize intrinsic protein
ﬂuorescence, but also to determine the contribution of certain Trps
to the Pgp ﬂuorescence signal. Trp ﬂuorescence spectra of Wt and
mutant Pgp proteins are shown in Fig. 7. The Wt emission spectrum
was shifted to shorter wavelengths (maximum at 327 nm) when
compared to the tryptophan analog NATA (356 nm), as previously
reported, suggesting that the native tryptophans are mostly in a
hydrophobic environment [27]. Assuming a quantum yield of 0.13 for
NATA [51], the average quantum yield of the eleven Wt Trps was esti-
mated to be 0.17. The Wt emission maximum at 327 nm did not shift
signiﬁcantly when two or four Trps were removed (Fig. 7). However,
the emission intensity did decrease with subsequent removal of Trps.
The W228F/W311Y and W694L/W1104Y mutations contributed to ap-
proximately 11±7% and 14%±11% decreases in emission, respectively,
while the Quadmutant emissionwas approximately 34%±7% less than
Wt. Overall, the intrinsic ﬂuorescent signal decreased proportionately
with the number of Trps removed (Supplemental Fig. 3). Removing
four of the eleven endogenous Trps resulted in a 1/3 reduction in intrin-
sic ﬂuorescence. Taking into account the rather high average quantum
yield, the data suggest that most, if not all Trp residues contribute to
the intrinsic Pgp ﬂuorescence, in contrast to a previous report conclud-
ing that the intrinsic ﬂuorescence arises from a few emitters [49].
3.6. Drug binding to Wt and quad mutant proteins
To compare the drug binding properties of Wt and quad mutant
proteins we used the ﬂuorescent transport substrate rhodamine 123
that produced strong Trp ﬂuorescence quenching upon binding to
Wt Pgp [27]. Experiments were carried out in the presence of phos-
pholipid PMPC dissolved in 0.125% (2 mM) CHAPS, which gave low
background ﬂuorescence. Addition of rhodamine 123 resulted in a
concentration-dependent Trp ﬂuorescence quench that was similar
in the Wt and quad mutant. Half-maximal quenching occurred at
80±7 μM and 77±11 μM in Wt and the quad mutant, respectively
(Fig. 8), indicating unaltered binding afﬁnity of the quad mutant.
Hill coefﬁcients of 1.6 and 1.9 suggest positive cooperativity between
two binding sites in both proteins. Wt Pgp contains eight Trps in the
TMDs (Fig. 1), close enough to the drug binding sites to serve as a
FRET donor to Rhodamine 123 assuming a characteristic FRET transfer
distance R0 of 17 Å of this donor/acceptor pair. The Quad mutant has
W228F/W311Y/W694L/W1104Y substituted, three of which are
located in the membrane. The similar quenching characteristics
between Wt and quad mutant suggest that most or all of the eight
transmembrane Trps contribute to the quench seen upon binding of
rhodamine 123 to Wt Pgp.
4. Discussion
Most Trps are highly conserved among Pgp species suggesting a
role of Trps in maintaining the structural stability of the protein, the
architecture of the drug binding sites and/or speciﬁc interactions
with hydrophobic drug substrates [52,53]. This study addresses two
basic questions: A) Can every one of the eleven native Trps in Pgp be
substituted while retaining function? B) Can multiple Trp substitutions
be combined into a low-Trp Pgp (several Trps replaced) that is fully
functional and expressed at wild-type levels? To answer these ques-
tions we chose “traditional” substitutions (tyrosine and phenylalanine)
with respect to the particular location within the membrane and
in intracellular domains (Fig. 1), or amino acids found in Pgp orthologs
(W44R and W694L). Only four single Trp mutants fully retained their
ability to convey resistance against a diverse set of antifungal drugs
and to complement for Ste6, the yeast a-factor pheromone transporter
required for mating (Figs. 2 and 3). Among them were W228F and
W311Y located within the membrane bilayer, W694L at the beginning
Fig. 6. Drug stimulate/inhibited ATPase activity of puriﬁed Trp mutant protein. Wt and mutant proteins were assayed for ATPase activity in increasing concentrations of verapamil
(A), valinomycin (B), FK506 (C), and cyclosporin A with 150 μM verapamil (D). Data points indicate the average speciﬁc activity from multiple time points±SEM from at least four
independent experiments, relative to the maximum Wt activity. Where not visible, error bars are smaller than the symbols. Lines represent non-linear regression analysis of the
data points with a Hill equation. R2 values for the data ﬁts were between 0.97 and 0.99. Kinetic parameters of the data ﬁts are given in Table 2.
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face, and W1104Y in NBD2. Those could be combined into pair
(W228F/W311Y and W694L/W1104Y) and quadruple (W228F/
W311Y/W694L/W1104Y) mutants that were fully active in yeast
assays (Fig. 4). Furthermore the pair and quad mutants could be puri-
ﬁed to homogeneity in yields similar to Wt protein, and displayed drug-
stimulated ATPase activity with binding afﬁnities very similar to Wt
Pgp (Tables 1 and 2). The intrinsic Trp ﬂuorescence of the pair and
quad mutants was reduced approximately proportionally to the number
of Trps removed with ~35% reduction achieved in the quad mutant.
Together these ﬁndings provide convincing evidence that polyspeciﬁcity
for diverse transport substrates was preserved when fully active single
Trp mutants were combined into a low-Trp Pgp.
This study also shed some light into those Trp residues that cannot
be simply replaced by an aromatic amino acid without adverselyTable 2
Drug-stimulated ATPase activity of Wt and Trp mutant proteins.
Verapamil a Ks(μM) b Valinomycina
Wt 5.1 9.7±0.5 5.5
W228F/W311Y 5.2 16±1.2 5.5
W694L/W1104Y 2.7 9.0±0.7 3.7
Quad 4.0 16±3.1 4.4
a Fold maximum stimulation of ATPase activity at 150 μM verapamil, 70 μM valinomycin
b Concentration required for half-maximal ATPase activity derived from plots of V vs. [dr
c Cyclosporin A concentration required for half maximal inhibition of verapamil-stimulataffecting protein expression, folding and/or function. Strikingly, sev-
eral single Trp mutants retained high levels of drug resistance against
FK506 (and other drugs) but showed severely impaired mating
efﬁciency (Fig. 2A vs. B). Examples are W132Y and W704Y, situated
at the cytoplasmic membrane interface, as well as W159F and
W799F, located in the coupling helices that connect the TMDs to the
NBDs. It is worth mentioning that in drug resistance assays, yeast
cells are continuously exposed over a prolonged time (>24 h) to
the drug that may act in the manner of chemical chaperones and
enhance folding and trafﬁcking of the mutant proteins to the cell
surface [54–56]. In contrast, mating is dependent on secretion of
a-factor pheromone and only mutants that trafﬁc normally to the cell
surface and retain their ability to export the pheromone will attract
α-tester cells and mate efﬁciently. The latter may account for the
more stringent discrimination ofmutant function seen inmating assays.Ks(μM) b FK506a Ks(μM)b Cyclosporin A Ki (μM)c
16±0.9 4.0 4.7±1.3 12±1.5
12±0.7 4.2 4.0±0.7 11±1.0
15±2.7 2.1 1.6±0.4 15±2.0
12±1.5 3.3 2.8±0.3 10±2.0
and 20 μM FK506.
ug] in Fig. 6A, B, and C, ﬁtted for a single exponential (mean±SEM).
ed ATPase (Fig. 6D) (mean±SEM).
Fig. 7. Intrinsic Trp ﬂuorescence of Wt and mutant Pgp. 100 nM puriﬁed Pgp in 0.1%
DDM solutions were excited at 295 nm and the ﬂuorescent emission spectra were
collected from 310 to 410 nm. Lines represent the average corrected emission spectra
from three independent experiments normalized to the maximum emission of Wt Pgp.
The emission maxima of all four proteins occurred between 325 and 228 nm.
For comparison, the emission spectra of a 1 μM solution of the Trp analog NATA is
also shown.
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brane surface because, like Trp, it can orient its polar side chain towards
the polar phospholipid head groups of themembrane bilayer (‘snorkel-
ing’ effect) and anchor helices in the membrane [43–45,52]. However
for some tyrosine substitutions, interactions with the membrane inter-
face alone may not fully account for the diverse phenotypes observed.
For example, in the inside-facing conformation of the Pgp crystal struc-
ture the indole side chain ofW132 points to the inside of the drug bind-
ing cavity andmay thereby interact not only with the lipid interface but
also directly contact some substrates by participating in H-bonding,
cation-bonding, and aromatic stacking interactions. Effects on substrate
speciﬁcity similar to W132Y were previously observed for tyrosine as
well as phenylalanine substitutions of Trps located in the TMDs of
the related multidrug ABC transporters MRP1, MRP2 and MRP3
[53,57–59]. Other examples are W704 that is situated at the turn ofFig. 8. Effect of binding of rhodamine 123 on the intrinsic Trp ﬂuorescence of Wt and
mutant Pgp. 100 nM puriﬁed Wt, 150 nM quad mutant Pgp or 1.5 μM NATA in
0.5 mg/ml PMPC/0.125 CHAPS solutions were excited at 295 nm and ﬂuorescent
emission spectra were collected after successive additions of rhodamine 123 (0.01 to
180 μM). Data points indicate the average Trp quenching (at 327 nm) of Wt and
quad mutant±SEM from four independent experiments, relative to the maximum
Trp ﬂuorescence, corrected for inner ﬁlter effects (NATA). Lines represent non-linear
regression analyses of the data points; R squared values were 0.998 and 0.990 for Wt
and quad mutants, respectively.the elbowhelix and the ﬁrstα-helix of TMD2, orW208 andW851 locat-
ed in the two very short extracellular loops. Possibly, a tyrosine substi-
tution at these positions may experience additional stereochemical
constraints leading to slight folding defects that can be ‘rescued’ by
some drugs (in resistance assays) but are detectable in mating assays.
Notably, W208Y was not only severely impaired in mating but also
showed signiﬁcantly reduced resistance to two of the drugs, FK506
and doxorubicin. The defects point to a severe interference with the
architecture of the drug binding sites that could not be rescued by
those drugs.
W158 and W799 are situated in the coupling helices that embed
into a groove on the NBDs. These are distant from the drug binding
sites but may be important in stabilizing the hairpin structure of the
coupling helices for proper connection. A phenylalanine is found at
the homologous positions of the related bacterial ABC transporters
MsbA and Sav1866 [46,47]. However, phenylalanine substitutions of
W158 and W799 in Pgp led to severely impaired mating efﬁciencies.
It is currently not well understood how coupling signals are transmitted
between NBDs and TMDs and whether they differ between ABC
proteins transporting different substrates. The severe defects seen in
W158F and W799F point to the importance of properly coupled inter-
domain communication in Pgp.
Finally, it is appropriate to comment on the tryptophan-deﬁcient
Pgp protein that was previously constructed by replacing all eleven
endogenous Trps with phenylalanine (Mdr3F1-11) [31]. That protein
exhibited altered drug resistance patterns in mammalian cells. It also
did not confer FK506 resistance nor could it functionally complemented
Ste6, perhaps due to severely compromised protein expression in yeast,
and has not been deployed in Trp ﬂuorescence studies. Chimeric
constructs between Wt and the Mdr3F1-11 mutant suggested that
reduced activity was not caused by loss of any uniquely important Trp
but rather a cumulative loss of several Trps. Interestingly, several studies
on gradient-driven transporters showed that those proteins are much
more tolerant to the straight-forward strategy of replacing Trp byphenyl-
alanine. Successful examples are the outermembraneproteinA (ﬁve Trps
replaced) [60], the lac permease (six Trps replaced) [30], the Na+/H+
antiporter NhaA from E. coli (six Trps replaced) [24], and the human
sodium/glucose cotransporter SGLT1 (13 replaced and one was essential
for function) [29]. In contrast, for Pgp the current study highlights the
importance of thoroughly testing individual Trp substitutions before
attempting to combine mutations into a low-tryptophan Pgp protein
that is functional. This was exempliﬁed in the N-triple mutant, a combi-
nation of W132Y, W158F and W311Y substitutions that individually
were all highly resistant to FK506, but each mutant showed signiﬁcantly
reduced resistance to one of the other drugs andW132Y andW158F also
showed impaired mating efﬁciencies; this N-triple combination com-
pletely lost function (Fig. 4). In stark contrast, combining W228F,
W311Y, W694L, and W1104Y, which each maintained high activity in
FK506 resistance and mating assays resulted in a fully active protein
that could be puriﬁed in sufﬁcient quantities and biochemically cha-
racterized (Figs. 5 and 6). The puriﬁed pair (W228F/W311Y and
W694L/W1104Y) and Quad (W228F/W311Y/W694L/W1104Y) mu-
tants exhibited levels of drug stimulated ATPase activity similar to Wt
Pgp with multiple drugs, conﬁrming that as a whole polyspeciﬁcity
was maintained in these mutants.
The intrinsic ﬂuorescence of the Quad mutant, although reduced
by ~1/3 compared to Wt Pgp, remains too high for site-speciﬁc drug
binding studies. This was exempliﬁed in Trp ﬂuorescence quenching
studies using the ﬂuorescent transport substrate rhodamine 123.
Rhodamine, like many Pgp substrates, absorbs light between 300 to
400 nm and can serve as FRET acceptor from Trps in close proximity
(calculated R0 at which 50% transfer occurs is 17 Å). Wt Pgp contains
eight Trps in the TMDs that are within 15 to 25 Å from the QZ59-SSS
binding sites; except W44 that is ~40 Å away (Fig. 1). The exact loca-
tion of the rhodamine binding site(s) in Pgp is currently unknown.
The similar quenching characteristics of Wt and the quad mutant,
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suggest two binding site for rhodamine that are likely within FRET range
of most of the eight transmembrane Trps in Wt Pgp (ﬁve in the quad
mutant) and contribute to the quenching either by FRET or due to
perturbation of the Trp probe's immediate environment.
We conclude that Trp removal is a challenging task especially for
complex systems such as mammalian ABC transporters containing
multiple TMDs and large cytoplasmic domains [53]. Many individual
substitutions of Trps at the membrane surface signiﬁcantly reduced
Pgp drug resistance and/or yeast cell mating efﬁciency suggesting
that they are important in maintaining polyspeciﬁcity and functional
integrity of the drug binding sites. However, four mutants, W228F,
W311Y, W694L, and W1104Y (three of which are located in the
membrane) and their combinations retained high drug resistance
and yeast cell mating in vivo as well as drug-stimulated ATPase
activities similar to WT Pgp. Removal of those four Trp residues
reduced the intrinsic ﬂuorescence of Pgp, but not enough for its use
in site-speciﬁc drug binding studies. Together, these results are a ﬁrst
step toward understanding the role of Trps in Pgp and towards the
development of a tryptophan-less Pgp, that will be vital for studying
the drug binding and transport mechanism of Pgp.
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